Carlos Slim Center for Health Research

Launched in partnership with the Carlos Slim Foundation, the center spanned researchers from the ӳý, the Carlos Slim Health Institute, other research institutions in Mexico, and elsewhere.

The Carlos Slim Center for Health Research’s main vehicle has been the Slim Initiative in Genomic Medicine for the Americas (SIGMA)—a powerful research program created by a historic partnership between the Carlos Slim Foundation and the ӳý.

Although type 2 diabetes is a major public health problem across the globe, Latin American countries carry a disproportionately heavy burden (relative rates of type 2 diabetes by country shown in purple above). ӳý researchers and their collaborators have discovered a strong genetic risk factor for type 2 diabetes that primarily affects Latin American patients, but is rare elsewhere.

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer. The findings also shed light on the role human papillomavirus (HPV) plays in the development of cervical cancer.